Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics.
asthma
benralizumab
eosinophil
mepolizumab
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
19
04
2023
accepted:
07
08
2023
medline:
20
11
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
This study compared the clinical outcomes of severe asthmatics treated with mepolizumab and benralizumab in a tertiary care severe asthma service setting. Patient data at baseline, six and 12 months were collected prospectively at two large tertiary hospital severe asthma clinics following treatment initiation. Two hundred and four patients received treatment with mepolizumab (117) or benralizumab (87). Baseline characteristics between groups were similar in regard to age, gender, body mass index, steroid dose and blood eosinophil count. However, the mepolizumab cohort had a higher Asthma Control Questionnaire Score (ACQ) at baseline (4.0 ± 1.1 vs. 3.6 ± 0.9, p = 0.018), accompanied by more frequent reliever medication usage and lower prebronchodilator FEV After 6 months treatment, both treatments induced significant improvements in (i) ACQ of 2.3 ± 0.1 (p < 0.001), (ii) oral steroid requiring exacerbations (incident rate ratio 0.26 (0.18-0.37), p < 0.001) and (iii) FEV In this large group of severe eosinophilic asthmatics, mepolizumab and benralizumab both improved disease parameters. However, benralizumab treatment appeared significantly more effective than mepolizumab in reducing exacerbations, improving FEV
Sections du résumé
BACKGROUND AND OBJECTIVE
This study compared the clinical outcomes of severe asthmatics treated with mepolizumab and benralizumab in a tertiary care severe asthma service setting.
METHODS
Patient data at baseline, six and 12 months were collected prospectively at two large tertiary hospital severe asthma clinics following treatment initiation. Two hundred and four patients received treatment with mepolizumab (117) or benralizumab (87). Baseline characteristics between groups were similar in regard to age, gender, body mass index, steroid dose and blood eosinophil count. However, the mepolizumab cohort had a higher Asthma Control Questionnaire Score (ACQ) at baseline (4.0 ± 1.1 vs. 3.6 ± 0.9, p = 0.018), accompanied by more frequent reliever medication usage and lower prebronchodilator FEV
RESULTS
After 6 months treatment, both treatments induced significant improvements in (i) ACQ of 2.3 ± 0.1 (p < 0.001), (ii) oral steroid requiring exacerbations (incident rate ratio 0.26 (0.18-0.37), p < 0.001) and (iii) FEV
CONCLUSION
In this large group of severe eosinophilic asthmatics, mepolizumab and benralizumab both improved disease parameters. However, benralizumab treatment appeared significantly more effective than mepolizumab in reducing exacerbations, improving FEV
Substances chimiques
mepolizumab
90Z2UF0E52
Anti-Asthmatic Agents
0
benralizumab
71492GE1FX
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1117-1125Informations de copyright
© 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Références
Buhl R, Humbert M, Bjermer L, Chanez P, Heaney L, Pavord I, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49:1700634.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659. https://doi.org/10.1016/S0140-6736(12)60988-X
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. https://doi.org/10.1056/NEJMoa140329
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141. https://doi.org/10.1016/S0140-6736(16)31322-8
Nair P, Wenzel S, Rabe KF, Bordin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448-2458. https://doi.org/10.1056/NEJMoa1703501
Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151. https://doi.org/10.1183/13993003.00151-2020
Kavanagh JE, Hearn AP, Dhariwal J, d'Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021 Feb;159(2):496-506. https://doi.org/10.1016/j.chest.2020.08.2083
Pelaia C, Crimi C, Benfante A, Caiaffa M, Calabrese C, Carpagnano G, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. J Asthma Allergy. 2021;14:163-173.
Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018 May 10;2018:4839230. https://doi.org/10.1155/2018/4839230
Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018 Nov 29;52(5):1801393. https://doi.org/10.1183/13993003.01393-2018
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019 Jan;143(1):190-200.e20. https://doi.org/10.1016/j.jaci.2018.08.031
Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. https://doi.org/10.1002/14651858.CD010834.pub3
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J Asthma Allergy. 2021 Jul 12;14:863-871. https://doi.org/10.2147/JAA.S319572
Australian Government Services Australia. Severe asthma-adolescent and adult initial and recommencement after 12 months break authority application form. 2021 [accessed 2021 Oct 20] Available from: https://www.servicesaustralia.gov.au/organisations/health-professionals/forms/pb075
Department of Health, Australia. The pharmaceutical benefits scheme (PBS): benralizumab. 2021 [accessed 2021 Oct 20] Available from: https://www.pbs.gov.au/medicine/item/11504L-11523L-11529T-11549W
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-1343. https://doi.org/10.1183/09031936.00080312
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. https://doi.org/10.1164/rccm.201908-1590ST
Diez-Roux AV. Multilevel analysis in public health research. Annu Rev Public Health. 2000;21:171-192.
Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29:190137. https://doi.org/10.1183/16000617.0137-2019
Elsey L, Hince K, Aspin P, Pantin C, Allen D, Niven R, et al. P101 outcomes with mepolizumab and benralizumab in severe eosinophilic asthma. Thorax. 2021;76:A142. https://doi.org/10.1136/thorax-2020-btsabstracts.246
Kavanagh J, Hearn A, Dhariwal J, d'Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe asthma. Chest. 2021;159(2):496-506.
Maglio A, Vitale C, Pelaia C, Amato M, Ciampo L, Sferra E, et al. Severe asthma remissions induced by biologics targeting IL5/IL5r: results from a multicentre real-life study. Int J Mol Sci. 2023;24:2455.
Kavanagh JE, Hearn AP, D'Ancona G, Dhariwal J, Roxas C, Green L, et al. Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma. Allergy. 2021;76:1890-1893. https://doi.org/10.1111/all.14693
Mallah N, Rodriguez-Segade S, Gonzalez-Barcala F, Takkouche B. Blood eosinophil count as predictor of asthma exacerbation: a meta-analysis. Pediatr Allergy Immunol. 2021;32:465-478. https://doi.org/10.1111/pai.13403